{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:55:50Z","timestamp":1787871350659,"version":"build-2784847793"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.cca.2026.121010","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T06:57:46Z","timestamp":1776322666000},"page":"121010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Cerebrospinal fluid biomarkers in Alzheimer's disease: enhancing diagnostic precision and guiding therapeutic strategies"],"prefix":"10.1016","volume":"589","author":[{"given":"Askarov Pulat","family":"Azadovich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behruz","family":"Oralov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjayev","family":"Sherzod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulchekhra","family":"Kudeshova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akramova","family":"Feruza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babajanova","family":"Umida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oydin","family":"Kambarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raupov","family":"Farkhod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanoyev","family":"Baxtiyor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuldashev","family":"Jurabek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumri","family":"Narzikulova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saodat","family":"Nazirova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saida","family":"Egamberdieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.cca.2026.121010_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10040850","article-title":"Development of alzheimers disease biomarkers: from CSF-to blood-based biomarkers","volume":"10","author":"Mankhong","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.cca.2026.121010_bb0010","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3389\/fnins.2015.00345","article-title":"The past and the future of alzheimer\u2019s disease CSF biomarkers a journey toward validated biochemical tests covering the whole spectrum of molecular events","volume":"9","author":"Blennow","year":"2015","journal-title":"Front. Neurosci."},{"issue":"2","key":"10.1016\/j.cca.2026.121010_bb0015","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3233\/JAD-2009-1177","article-title":"Cerebrospinal fluid biomarkers for alzheimer\u2019s disease","volume":"18","author":"Blennow","year":"2009","journal-title":"J. Alzheimer\u2019s Dis"},{"issue":"2","key":"10.1016\/j.cca.2026.121010_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci11020215","article-title":"Cerebrospinal fluid biomarkers of alzheimers disease: current evidence and future perspectives","volume":"11","author":"McGrowder","year":"2021","journal-title":"Brain Sci."},{"issue":"1","key":"10.1016\/j.cca.2026.121010_bb0025","article-title":"Clinical application of CSF biomarkers for alzheimer\u2019s disease: from rationale to ratios","volume":"14","author":"Bouwman","year":"2022","journal-title":"Alzheimer\u2019s & Dementia: Diagnosis, Assessment & Disease Monitoring"},{"issue":"1","key":"10.1016\/j.cca.2026.121010_bb0030","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2217\/bmm.09.83","article-title":"Cerebrospinal fluid biomarkers of alzheimer\u2019s disease","volume":"4","author":"Fagan","year":"2010","journal-title":"Biomark. Med"},{"key":"10.1016\/j.cca.2026.121010_bb0035","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.neurobiolaging.2011.09.003","article-title":"CSF biomarkers for alzheimer\u2019s disease: current utility and potential future use","volume":"32","author":"Holtzman","year":"2011","journal-title":"Neurobiol. Aging"},{"issue":"1","key":"10.1016\/j.cca.2026.121010_bb0040","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3233\/JAD-160573","article-title":"Cerebrospinal fluid biomarkers for alzheimers disease: A view of the regulatory science qualification landscape from the coalition against major diseases CSF biomarker team","volume":"55","author":"Arneri\u0107","year":"2016","journal-title":"J. Alzheimer\u2019s Dis"},{"issue":"10","key":"10.1016\/j.cca.2026.121010_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24108976","article-title":"CSF biomarkers in the early diagnosis of mild cognitive impairment and alzheimers disease","volume":"24","author":"Papaliagkas","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"Suppl. 1","key":"10.1016\/j.cca.2026.121010_bb0050","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40120-017-0073-9","article-title":"A review of fluid biomarkers for alzheimers disease: Moving from CSF to blood","volume":"6","author":"Blennow","year":"2017","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.cca.2026.121010_bb0055","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1002\/alz.13399","article-title":"Cerebrospinal fluid biomarkers in the longitudinal early-onset alzheimer\u2019s disease study","volume":"19","author":"Dage","year":"2023","journal-title":"Alzheimers Dement."},{"issue":"4","key":"10.1016\/j.cca.2026.121010_bb0060","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1212\/WNL.0000000000207193","article-title":"Blood biomarkers in neurodegenerative diseases: implications for the clinical neurologist","volume":"101","author":"Alcolea","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.cca.2026.121010_bb0065","doi-asserted-by":"crossref","first-page":"143","DOI":"10.3389\/fneur.2015.00143","article-title":"Preanalytical confounding factors in the analysis of cerebrospinal fluid biomarkers for alzheimers disease: the issue of diurnal variation","volume":"6","author":"Cicognola","year":"2015","journal-title":"Front. Neurol."},{"issue":"6","key":"10.1016\/j.cca.2026.121010_bb0070","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jalz.2014.03.003","article-title":"The clinical use of cerebrospinal fluid biomarker testing for alzheimer\u2019s disease diagnosis: A consensus paper from the alzheimer\u2019s biomarkers standardization initiative","volume":"10","author":"Molinuevo","year":"2014","journal-title":"Alzheimers Dement."},{"issue":"8","key":"10.1016\/j.cca.2026.121010_bb0075","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.neurobiolaging.2011.05.013","article-title":"Serial CSF sampling in alzheimer\u2019s disease: specific versus nonspecific markers","volume":"33","author":"Kester","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.cca.2026.121010_bb0080","doi-asserted-by":"crossref","first-page":"51","DOI":"10.14283\/jpad.2022.97","article-title":"15th conference clinical trials alzheimers disease, november 29\u2013December 2, 2022, San Francisco, CA, USA: posters","volume":"9","author":"Ljubenkov","year":"2022","journal-title":"J. Prev Alzheimers Dis."},{"issue":"4","key":"10.1016\/j.cca.2026.121010_bb0085","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3233\/JAD-2011-101911","article-title":"Longitudinal changes of CSF biomarkers in alzheimer\u2019s disease","volume":"25","author":"Sepp\u00e4l\u00e4","year":"2011","journal-title":"J. Alzheimer\u2019s Dis"},{"issue":"s1","key":"10.1016\/j.cca.2026.121010_bb0090","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.3233\/JAD-240610","article-title":"Serial cerebrospinal fluid sampling reveals trajectories of potential synaptic biomarkers in early stages of alzheimers disease","volume":"100","author":"Duits","year":"2024","journal-title":"J. Alzheimer\u2019s Dis"},{"key":"10.1016\/j.cca.2026.121010_bb0095","doi-asserted-by":"crossref","first-page":"100385","DOI":"10.1016\/j.prdoa.2025.100385","article-title":"Safety and feasibility of serial lumbar punctures: Long-term results from the parkinson\u2019s progression markers initiative","author":"Barbosa","year":"2025","journal-title":"Clinical parkinsonism & related disorders"},{"issue":"4","key":"10.1016\/j.cca.2026.121010_bb0100","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/01.wad.0000194014.43575.fd","article-title":"Safety and acceptability of the research lumbar puncture","volume":"19","author":"Peskind","year":"2005","journal-title":"Alzheimer Dis. Assoc. Disord."},{"issue":"20","key":"10.1016\/j.cca.2026.121010_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262010107","article-title":"Surrogate biomarkers in gene therapy for orphan diseases: validation, application, and regulatory aspects","volume":"26","author":"Ayupova","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.cca.2026.121010_bb0110","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/17576180.2024.2442218","volume":"17","author":"Bivi","year":"2025","journal-title":"Bioanalysis"},{"issue":"2","key":"10.1016\/j.cca.2026.121010_bb0115","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/jnc.15465","article-title":"Mass spectrometry-based methods for robust measurement of alzheimer\u2019s disease biomarkers in biological fluids","volume":"159","author":"Korecka","year":"2021","journal-title":"J. Neurochem."},{"key":"10.1016\/j.cca.2026.121010_bb0120","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.neurobiolaging.2016.02.034","article-title":"Clinical validity of cerebrospinal fluid a\u03b242, tau, and phospho-tau as biomarkers for alzheimer\u2019s disease in the context of a structured 5-phase development framework","volume":"52","author":"Mattsson","year":"2017","journal-title":"Neurobiol. Aging"},{"issue":"1","key":"10.1016\/j.cca.2026.121010_bb0125","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41398-025-03345-z","article-title":"Clinical utility of cerebrospinal fluid alzheimers disease biomarkers in the diagnostic workup of complex patients with cognitive impairment","volume":"15","author":"Wang","year":"2025","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.cca.2026.121010_bb0130","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13195-019-0550-8","article-title":"Clinical validation of the lumipulse g cerebrospinal fluid assays for routine diagnosis of alzheimers disease","volume":"11","author":"Leit\u00e3o","year":"2019","journal-title":"Alzheimer\u2019s Res. Ther."},{"issue":"1","key":"10.1016\/j.cca.2026.121010_bb0135","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13195-020-00596-4","article-title":"Cerebrospinal fluid phospho-tau t217 outperforms t181 as a biomarker for the differential diagnosis of alzheimers disease and PET amyloid-positive patient identification","volume":"12","author":"Barth\u00e9lemy","year":"2020","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"10.1016\/j.cca.2026.121010_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103836","article-title":"Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in alzheimer\u2019s disease","volume":"76","author":"Ashton","year":"2022","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.cca.2026.121010_bb0145","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/acn3.266","article-title":"Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of alzheimer\u2019s disease","volume":"3","author":"Janelidze","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"1","key":"10.1016\/j.cca.2026.121010_bb0150","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13195-015-0142-1","article-title":"Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor alzheimers disease in a memory clinic cohort","volume":"7","author":"Kester","year":"2015","journal-title":"Alzheimer\u2019s Res. Ther."},{"issue":"1","key":"10.1016\/j.cca.2026.121010_bb0155","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13195-018-0353-3","article-title":"Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in alzheimers disease","volume":"10","author":"Brosseron","year":"2018","journal-title":"Alzheimer\u2019s Res. Ther."},{"issue":"2","key":"10.1016\/j.cca.2026.121010_bb0160","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/ana.26822","article-title":"Diagnostic utility of cerebrospinal fluid biomarkers in patients with rapidly progressive dementia","volume":"95","author":"Kuchenbecker","year":"2024","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.cca.2026.121010_bb0165","article-title":"Cerebrospinal fluid proteomics identification of biomarkers for amyloid and tau PET stages","volume":"6","author":"Wang","year":"2025","journal-title":"Cell Rep Med."},{"issue":"3","key":"10.1016\/j.cca.2026.121010_bb0170","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcae132","article-title":"CSF neurofilament light chain profiling and quantitation in neurological diseases","volume":"6","author":"Leckey","year":"2024","journal-title":"Brain Commun."},{"key":"10.1016\/j.cca.2026.121010_bb0175","unstructured":"Allen C, Smits B, Smith C. The NEALS Consortium: Thirty Years of Advancing Amyotrophic Lateral Sclerosis (ALS) Research through Collaboration and Innovation. InMUSCLE & NERVE 2025 Oct 1 (Vol. 72, pp. S1-S97). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY."},{"issue":"11\u221212","key":"10.1016\/j.cca.2026.121010_bb0180","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/14789450.2025.2604161","article-title":"Future of clinical proteomics: could targeted multiprotein panels supplant low-throughput methods?","volume":"22","author":"Ramesh","year":"2025","journal-title":"Expert Rev. Proteomics"},{"issue":"6","key":"10.1016\/j.cca.2026.121010_bb0185","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70241","article-title":"Development and validation of a novel simoa assay for NPTX2 in Alzheimer\u2019s disease and down syndrome","volume":"21","author":"Sauer","year":"2025","journal-title":"Alzheimers Dement."},{"issue":"1","key":"10.1016\/j.cca.2026.121010_bb0190","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13195-022-01021-8","article-title":"Quantification of SNAP-25 with mass spectrometry and simoa: A method comparison in alzheimers disease","volume":"14","author":"Nilsson","year":"2022","journal-title":"Alzheimer\u2019s Res. Ther."},{"issue":"1","key":"10.1016\/j.cca.2026.121010_bb0195","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41392-023-01399-3","article-title":"Small molecule metabolites: discovery of biomarkers and therapeutic targets","volume":"8","author":"Qiu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"9","key":"10.1016\/j.cca.2026.121010_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/metabo13091007","article-title":"Recent advances and perspectives in relation to the metabolomics-based study of diabetic retinopathy","volume":"13","author":"He","year":"2023","journal-title":"Metabolites"},{"issue":"10","key":"10.1016\/j.cca.2026.121010_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29102198","article-title":"Metabolomics for clinical biomarker discovery and therapeutic target identification","volume":"29","author":"Lin","year":"2024","journal-title":"Molecules"},{"issue":"7","key":"10.1016\/j.cca.2026.121010_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/metabo9070123","article-title":"NMR spectroscopy for metabolomics research","volume":"9","author":"Emwas","year":"2019","journal-title":"Metabolites"},{"issue":"1","key":"10.1016\/j.cca.2026.121010_bb0215","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40170-024-00367-x","article-title":"Exploratory profiling of metabolites in cerebrospinal fluid using a commercially available targeted LC\u2013MS based metabolomics kit to discriminate leptomeningeal metastasis","volume":"13","author":"Jang","year":"2025","journal-title":"Cancer Metab."},{"issue":"11","key":"10.1016\/j.cca.2026.121010_bb0220","article-title":"1H NMR metabolomic profiling of human cerebrospinal fluid in aging process","volume":"13","author":"Lin","year":"2021","journal-title":"Am. J. Transl. Res."},{"issue":"3","key":"10.1016\/j.cca.2026.121010_bb0225","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1021\/acs.analchem.3c03660","article-title":"QC omics: recommendations and guidelines for robust, easily implementable and reportable quality control of metabolomics data","volume":"96","author":"Gonz\u00e1lez-Dom\u00ednguez","year":"2024","journal-title":"Anal. Chem."},{"issue":"4","key":"10.1016\/j.cca.2026.121010_bb0230","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/anie.201804736","article-title":"High-throughput metabolomics by 1D NMR","volume":"58","author":"Vignoli","year":"2019","journal-title":"Angew. Chem. Int. Ed."},{"issue":"12","key":"10.1016\/j.cca.2026.121010_bb0235","doi-asserted-by":"crossref","first-page":"5860","DOI":"10.1002\/alz.13390","article-title":"Artificial intelligence for biomarker discovery in alzheimer\u2019s disease and dementia","volume":"19","author":"Winchester","year":"2023","journal-title":"Alzheimers Dement."},{"issue":"1","key":"10.1016\/j.cca.2026.121010_bb0240","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12987-025-00634-z","article-title":"Applying machine learning to high-dimensional proteomics datasets for the identification of alzheimers disease biomarkers","volume":"22","author":"Ivarsson Orrelid","year":"2025","journal-title":"Fluids Barriers CNS."},{"key":"10.1016\/j.cca.2026.121010_bb0245","article-title":"Artificial intelligence-based biomarkers for the diagnosis and treatment of neurological conditions: a narrative review","volume":"7","author":"Ben-Jaafar","year":"2026","journal-title":"Molecular Brain"},{"issue":"1","key":"10.1016\/j.cca.2026.121010_bb0250","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s13195-025-01789-5","article-title":"Machine-learning based strategy identifies a robust protein biomarker panel for alzheimers disease in cerebrospinal fluid","volume":"17","author":"Hou","year":"2025","journal-title":"Alzheimer\u2019s Res. Ther."},{"issue":"9","key":"10.1016\/j.cca.2026.121010_bb0255","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.neuron.2025.02.014","article-title":"Multicohort cerebrospinal fluid proteomics identifies robust molecular signatures across the alzheimer disease continuum","volume":"113","author":"Ali","year":"2025","journal-title":"Neuron"},{"key":"10.1016\/j.cca.2026.121010_bb0260","article-title":"Protein-based Diagnosis and Analysis of Co-pathologies Across Neurodegenerative Diseases: Large-Scale AI-Boosted CSF and Plasma Classification","author":"Xu","year":"2025","journal-title":"medRxiv"},{"issue":"1","key":"10.1016\/j.cca.2026.121010_bb0265","article-title":"Pre-analytical protocol for measuring Alzheimer\u2019s disease biomarkers in fresh CSF","volume":"12","author":"Hansson","year":"2020","journal-title":"Alzheimers Dement Diagn Assess Dis Monit."},{"issue":"9","key":"10.1016\/j.cca.2026.121010_bb0270","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/alz.12316","article-title":"The alzheimer\u2019s association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid \u03b2 and tau","volume":"17","author":"Hansson","year":"2021","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.cca.2026.121010_bb0275","series-title":"Cerebrospinal Fluid (CSF) Proteomics: Methods and Protocols","first-page":"27","article-title":"Guidelines for CSF processing and biobanking: Impact on the identification and development of optimal CSF protein biomarkers","author":"Hok-A-Hin","year":"2019"},{"issue":"4","key":"10.1016\/j.cca.2026.121010_bb0280","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11306-021-01848-6","article-title":"Reference materials for MS-based untargeted metabolomics and lipidomics: A review by the metabolomics quality assurance and quality control consortium (mQACC)","volume":"18","author":"Lippa","year":"2022","journal-title":"Metabolomics"},{"issue":"19","key":"10.1016\/j.cca.2026.121010_bb0285","doi-asserted-by":"crossref","first-page":"5967","DOI":"10.1158\/1078-0432.CCR-07-4535","article-title":"Validation of analytic methods for biomarkers used in drug development","volume":"14","author":"Chau","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.cca.2026.121010_bb0290","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.pathol.2023.11.002","article-title":"Biomarkers and biomarker validation: A pathologist\u2019s guide to getting it right","volume":"56","author":"Paver","year":"2024","journal-title":"Pathology"},{"issue":"1","key":"10.1016\/j.cca.2026.121010_bb0295","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/cpt.3661","article-title":"Participants in the FDA\u2019S biomarker qualification program","volume":"118","author":"Shahzad","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.cca.2026.121010_bb0300","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines14030557","article-title":"Neuroinflammatory biomarkers in chronic low back pain: mechanisms, clinical evidence, and translational challenges","volume":"14","author":"Pinheiro","year":"2026","journal-title":"Biomedicines"},{"issue":"17","key":"10.1016\/j.cca.2026.121010_bb0305","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26178564","article-title":"The role of blood-based biomarkers in transforming alzheimers disease research and clinical management: a review","volume":"26","author":"Pacoova Dal Maschio","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.cca.2026.121010_bb0310","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.3390\/biomedicines10051077","article-title":"Serum-based biomarkers in neurodegeneration and multiple sclerosis","volume":"10","author":"LoPresti","year":"2022","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.cca.2026.121010_bb0315","doi-asserted-by":"crossref","DOI":"10.1007\/s10072-026-08931-7","volume":"47","author":"Gaetani","year":"2026","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.cca.2026.121010_bb0320","series-title":"15th Conference Clinical Trials Alzheimer\u2019s Disease, November 29\u2013December 2, 2022, San Francisco, CA, USA","author":"Alzheimer","year":"2022"},{"issue":"7","key":"10.1016\/j.cca.2026.121010_bb0325","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","article-title":"Acceptable performance of blood biomarker tests of amyloid pathology recommendations from the global CEO initiative on alzheimers disease","volume":"20","author":"Schindler","year":"2024","journal-title":"Nat. Rev. Neurol."},{"issue":"8","key":"10.1016\/j.cca.2026.121010_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2025.101025","article-title":"Proteome profiling of cerebrospinal fluid and machine learning reveal protein classifiers of two forms of alzheimers disease characterized by increased or not altered levels of tau","volume":"24","author":"Scalia","year":"2025","journal-title":"Mol. Cell. Proteomics"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126001920?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126001920?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:20:50Z","timestamp":1781511650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898126001920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":66,"alternative-id":["S0009898126001920"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2026.121010","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cerebrospinal fluid biomarkers in Alzheimer's disease: enhancing diagnostic precision and guiding therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2026.121010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"121010"}}